Suppr超能文献

血清素受体拮抗剂赛庚啶对5,6-二甲基呫吨酮-4-乙酸(DMXAA)活性和药代动力学的影响。

Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA).

作者信息

Zhao L, Kestell P, Philpott M, Ching L M, Zhuang L, Baguley B C

机构信息

Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, New Zealand.

出版信息

Cancer Chemother Pharmacol. 2001 Jun;47(6):491-7. doi: 10.1007/s002800000267.

Abstract

BACKGROUND

DMXAA (5,6-dimethylxanthenone-4-acetic acid) is a new drug synthesized in this laboratory and currently in phase I clinical trial. In mice it acts as an antivascular drug, selectively inhibiting tumour blood flow and inducing tumour haemorrhagic necrosis with resultant tumour regression. It also induces the synthesis of tumour necrosis factor (TNF), nitric oxide and serotonin. Cyproheptadine, a type 2 serotonin receptor antagonist, is known to reduce the degree of tumour necrosis-induced TNF in mice. We investigated the pharmacological interaction between a suboptimal dose of DMXAA (20 mg/kg) and cyproheptadine (20 mg/ kg) using mice with Colon 38 tumours that are sensitive to DMXAA.

METHODS

Mice with or without tumours were treated with DMXAA and/or cyproheptadine. Concentrations of plasma and tissue DMXAA and the serotonin metabolite 5-hydroxyindoleacetic acid were measured by high performance liquid chromatography. TNF concentrations were measured by ELISA.

RESULTS

While DMXAA alone (20 mg/kg) showed little or no antitumour activity, coadministration with cyproheptadine was curative in four of five mice. DMXAA half-lives in plasma and tumour tissue were increased 5.1- and 5.6-fold, respectively, and the appearance of DMXAA glucuronides in bile was almost completely inhibited for up to 4 h. Serum TNF was low and unchanged by cyproheptadine, and plasma concentrations of the serotonin metabolite 5-hydroxyindoleacetic acid were also not substantially changed.

CONCLUSION

The augmentation by cyproheptadine of the induction of tumour response to DMXAA reflects a pharmacological interaction, leading to increased plasma and tumour half-lives, and to reduced excretion. However, serum TNF concentrations were not increased, suggesting that the increased anti-tumour effects are mediated by an increased local tumour response, arising from the extended tumour DMXAA concentrations.

摘要

背景

DMXAA(5,6 - 二甲基呫吨酮 - 4 - 乙酸)是本实验室合成的一种新药,目前正处于I期临床试验阶段。在小鼠中,它作为一种抗血管生成药物,选择性地抑制肿瘤血流并诱导肿瘤出血性坏死,从而导致肿瘤消退。它还能诱导肿瘤坏死因子(TNF)、一氧化氮和血清素的合成。赛庚啶是一种2型血清素受体拮抗剂,已知可降低小鼠中肿瘤坏死诱导的TNF水平。我们使用对DMXAA敏感的结肠38肿瘤小鼠,研究了次优剂量的DMXAA(20 mg/kg)与赛庚啶(20 mg/kg)之间的药理相互作用。

方法

对有或无肿瘤的小鼠给予DMXAA和/或赛庚啶治疗。通过高效液相色谱法测量血浆和组织中DMXAA以及血清素代谢产物5 - 羟吲哚乙酸的浓度。通过酶联免疫吸附测定法测量TNF浓度。

结果

单独使用DMXAA(20 mg/kg)时几乎没有或没有抗肿瘤活性,但与赛庚啶联合使用时,五只小鼠中有四只被治愈。DMXAA在血浆和肿瘤组织中的半衰期分别增加了5.1倍和5.6倍,并且在长达4小时内,胆汁中DMXAA葡糖醛酸化物的出现几乎被完全抑制。血清TNF水平较低,赛庚啶对其无影响,血清素代谢产物5 - 羟吲哚乙酸的血浆浓度也没有显著变化。

结论

赛庚啶增强了肿瘤对DMXAA的反应诱导作用,这反映了一种药理相互作用,导致血浆和肿瘤半衰期延长以及排泄减少。然而,血清TNF浓度并未升高,这表明增强的抗肿瘤作用是由肿瘤局部反应增强介导的,这是由于肿瘤中DMXAA浓度延长所致。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验